Selective estrogen receptor modulators

Clinical Reviews in Bone and Mineral Metabolism

Volumn 3, Issue 1, 2005, Pages 19-30

  Petersen, Nicole M ^a   Briggs, Amber L ^b  

^a ST LOUIS COLLEGE OF PHARMACY   (United States)

^b Soldotna Professional Pharmacy   (United States)

Author keywords

Bone mineral density; Fractures; Osteoporosis; Raloxifene; Selective estrogen receptor modulators; Tamoxifen; Toremifene

Indexed keywords

ALENDRONIC ACID; ARZOXIFENE; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLESTYRAMINE; ESTROGEN RECEPTOR; ETIDRONIC ACID; IDOXIFENE; LASOFOXIFENE; LIVER ENZYME; OSPEMIFENE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TAMOXIFEN CITRATE; TOREMIFENE; VITAMIN D; WARFARIN;

ARTHRALGIA; BONE DENSITY; BONE MINERALIZATION; BONE PAIN; BREAST CANCER; BREAST TENDERNESS; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CATARACT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CORNEA DISEASE; DEEP VEIN THROMBOSIS; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; ENDOMETRIAL DISEASE; ENDOMETRIAL THICKENING; ENDOMETRIOSIS; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; EYE DISEASE; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HOT FLUSH; HUMAN; HYPERCALCEMIA; INFLUENZA; LEG CRAMP; LEUKORRHEA; LUMBAR SPINE; META ANALYSIS; NAUSEA; PATIENT EDUCATION; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RECEPTOR BINDING; RETINOPATHY; REVIEW; SIDE EFFECT; STATISTICAL SIGNIFICANCE; STROKE; SWEATING; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; THROMBOEMBOLISM; UTERUS MYOMA; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; VERTIGO; VOMITING;

EID: 26244434718     PISSN: 15348644     EISSN: None     Source Type: Journal    
DOI: 10.1385/bmm:3:1:019     Document Type: Review

References (65)

1. Rossouw JE, Anderson GL, Prentice RL, et al. 2002 Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.
2. Morello KC, Wurz GT, DeGregorio MW. 2002 SERMs: current status and future trends. Crit Rev Oncol Hematol 43:63-76.
3. Grese TA, Sluka JP, Bryant HU, et al. 1997 Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 94:14,105-14,110.
4. Mitlak BH, Cohen FJ. 1999 Selective estrogen receptor modulators: a look ahead. Drugs 57:653-663.
5. Khovidhunkit W, Shoback DM. 1999 Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 150:431-439.
6. Hodgson SF, Watts NB, Bilezikian JP, et al; AACE Osteoporosis Task Force. 2003 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 9:544-564.
7. Walsh BW, Kuller LH, Wild RA, et al. 1998 Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445-1451.
8. Cranney A, Tugwell P, Zytaruk N, et al; and the Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 23:524-528.
9. Maricic M, Gluck O. 2002 Review of raloxifene and its clinical applications in osteoporosis. Expert Opin Pharmacother 3:767-775.
10. Institute for Clinical Systems Improvement Health Care Guideline: Diagnosis and Treatment of Osteoporosis. Institute for Clinical Systems Improvement Website. Available at: www.icsi.org. Last accessed on October 1, 2004.
11. McClung M, Omizo M., Weiss S, Moffit et al. 2004 Comparison of lasofoxifene and raloxifene for the prevention of bone loss in postmenopausal women. J Bone Miner Met 19(Suppl 1):S96 (abstract).
12. McClung M, Portman D, Emkey R, et al. Comparison of the extraskeletal effects of lasofoxifene and raloxifene. J Bone Miner Met 2004 19(Suppl 1):S174 (abstract).
13. Johnston SR, Gumbrell LA, Evans TR, et al. 2004 A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. Cancer Chemother Pharmacol 53:341-348.
14. Nuttall ME, Bradbeer JN, Stroup GB, et al. 1998 Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats. Endocrinology 139:5224-5234.
15. Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O. 2003 Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 10:433-439.
16. Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD. 2004 Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 145:1996-2005.
17. Burke TW, Walker CL. 2003 Arzoxifene as therapy for endometrial cancer. Gynecol Oncol 90(2 Pt. 2):S40-S46.
18. Ma YL, Bryant HU, Zeng Q, et al. 2002 Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in overiectomized rats. J Bone Miner Res 17:2256-2264.
19. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD. 1995 Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 136:2435-2441
20. Bellmunt J, Sole L. 1991 European early phase II dose-finding study of droloxifene in advanced breast cancer. Am J Clin Oncol 14(Suppl 2):S36-S39.
21. Buzdar A, Hayes D, El-Khoudary A, et al. Droloxifene 301 Study Group. 2002 Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 73:161-175.
22. Ettinger B, Black DM, Mitlak BH, et al. 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637-645.
23. Kanis JA, Johnell O, Black DM, et al. 2003 Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33:293-300.
24. Delmas PD, Ensrud KE, Adachi JD, et al, and the Multiple Outcomes of Raloxifene Evaluation Investigators. 2002 Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609-3617.
25. Harris ST, Siris ES, Stock JL, et al. 2004 Increases in bone mineral density are maintained after 7 years of raloxifene therapy: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Met 19(Suppl 1):S56 (abstract).
26. Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. 2000 Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160:3444-3450.
27. Delmas PD, Genart HK, Crans GG, et al. 2003 Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522-532.
28. Siris ES, Harris ST, Eastell R, et al. 2004 Effects of raloxifene on the risk of nonvertebral fractures after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Met 19(Suppl 1): S96 (abstract).
29. Cranney A, Guyatt G, Griffith L, et al., and the Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570-578.
30. Boivin G, Lips P, Ott SM, et al. 2003 Contribution of raloxifene and calcium and vitamin D3 supplementation to the increase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab 88:4199-4205.
31. Holli K, Valavaara R, Blanco G, et al.2000 Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol 18:3487-3494.
32. Cummings SR, Palermo L, Browner W, et al. 2000 Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 283:1318-1321.
33. Jones KL, Buzdar AU. 2000 A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer 11:391-406.
34. Neele SJ, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC. 2002 Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30:599-603.
35. Love RR, Mazess RB, Barden HS, et al. 1992 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852-856.
36. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR. 1995 The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 99:636-641.
37. Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ. 1994 Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154:2585-2588.
38. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. 1998 Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83:1158-1162.
39. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. 2002 Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:985-992.
40. Ettinger B, Bilezikian JP. 2002 For osteoporosis, are two antiresorptive drugs better than one? J Clin Endocrinol Metab 87:983-984.
41. Ettinger B, San Martin J, Crans G, Pavo I. 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745-751.
42. Cosman F, Nieyes J, Barburn N, Zion M, Lindsay R. 2004 Parathyroid hormone added to raloxifene and subsequent maintenance of BMD gain with raloxifene alone. J Bone Miner Met 19(Suppl 1):S98 (abstract).
43. Osteoporosis Prevention, Diagnosis and Therapy. 2001 National Institutes of Health Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 285:785-795.
44. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society. 2002 J Am Menopause 9:84-101.
45. Kung AW, Chao HT, Huang KE, et al. 2003 Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women. J Clin Endocrinol Metab 88:3130-3136.
46. Uebelhart B, Herrmann F, Pavo I, Draper MW, Rizzoli R. 2004 Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J Bone Miner Res 19:1518-1524.
47. Osteoporosis Society of Canada. Available at: http://www.osteoporosis.ca. Last accessed on: October 3, 2004.
48. Roth M. Osteoporosis guidelines. Clin Rev Bone Miner Metab 2004 2: 315-324.
49. Duschek EJ, Gooren LJ, Netelenbos C. 2004 Effects of raloxifene on gonadotropins, sex hormones, bone turnover and lipids in healthy elderly men. Eur J Endocrinol 50:539-546.
50. Walsh BW, Paul S, Wild RA, Dean et al. 2000 The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 85:214-218.
51. Barrett-Connor E, Ensrud KE, Harper K, Mason et al. 2003 Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 25:919-930.
52. O'Riordan M. 2004 Use of raloxifene to prevent CHD: more data needed from the upcoming RUTH trial. Accessed at http://www.theheart.org/viewArticle.do? primaryKey=565061 on September 1, 2004.
53. Mosca L, Barrett-Connor E, Wenger NK, et al. 2001 Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 88:392-395.
54. Cummings SR, Eckert S, Krueger KA, et al. 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197.
55. Cauley JA, Norton L, Lippman ME, et al. 2001 Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125-134.
56. Barrett-Connor E, Powles TJ, Mershon JL, et al. 2004 Incidence of invasive breast cancer following 8 years of raloxifene therapy in postmenopausal women with osteoporosis: results from the Continuing Outcomes Relevant to Evista (CORE) trial. J Clin Onc 22(Suppl 14):1000 (abstract).
57. Schwartz J. 2004 Tamoxifen: an emerging preventive. Front Biosci 9:2827-2847.
58. No authors. 2000 STAR: first-year recruitment efforts set brisk pace for future. CA Cancer J Clin. 50:271-272.
59. Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ. 2004 Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner Res 19:1270-1275.
60. Cohen I, Rosen DJ, Shapira J, et al. 1994 Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 52:185-190.
61. Davies GC, Huster WJ, Lu Y, Plouffe L Jr, Lakshmanan M. 1999 Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 93:558-565.
62. Eli Lilly and Company. 2003 Evista (raloxifene hydrochloride tablets) prescribing information. Indianapolis, IN.
63. Fisher B, Costantino JP, Wickerham DL, et al. 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388.
64. Paganini-Hill A, Clark LJ. 2000 Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 60:167-172.
65. Delmas PD, Bjarnason NH, Mitlak BH, et al. 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641-1647.